Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...

Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...

Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it ...

Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The ...